Expression of c-erbB-2 protein in normal and neoplastic urothelium: lack of adverse prognostic effect in human urinary bladder cancer
- PMID: 7915094
Expression of c-erbB-2 protein in normal and neoplastic urothelium: lack of adverse prognostic effect in human urinary bladder cancer
Abstract
The clinical significance of c-erb B-2 expression in urinary bladder cancer remains controversial. We performed an immunohistochemical study to examine the expression of c-erb B-2 in non-neoplastic urothelium (n = 12) and transitional cell carcinoma of the urinary bladder (n = 82). c-erb B-2 protein was localized in superficial and some intermediate cells of non-neoplastic urothelium. A total of 29 out of 82 (35%) tumors were positive for c-erb B-2 over-expression. There was no significant association of c-erbB-2 expression with tumor grade (p = 0.12), stage (p = 0.93), DNA ploidy status (p = 0.56) and the sex of patients (p = 0.5). Expression of epidermal growth factor receptor and Ki-67 index was available in 33 cases. Both parameters showed no apparent association with c-erbB-2 expression (p = 0.53 and 0.58 respectively). Factors correlated with poor patient survival by univariate analysis were tumor stage (p = 0.0001), tumor grade (p = 0.001), development of second recurrence (p = 0.002) and negative expression of c-erbB-2 (p = 0.017). Important indicators associated with first recurrence were tumor stage (p = 0.028), and c-erbB-2 expression with the risk of second recurrence (p = 0.031). Multivariate survival analysis revealed that tumor stage was among the most important prognostic factors (p = 0.029), followed by tumors without c-erbB-2 expression (p = 0.031) with a median follow-up at 46 months. The age of patients and c-erbB-2 expression were significantly associated with developing second recurrence (p = 0.031 and 0.046 respectively). The results indicate that expression of c-erbB-2 is independent of the stage and grade of bladder cancer. Although c-erbB-2 status can discriminate subpopulations with a high risk of recurrence, evaluation of its expression in paraffin-embedded tumors does not indicate poor prognosis for patients with urinary bladder cancer. To address this discrepancy a better understanding of the regulatory mechanism and physiological properties of c-erbB-2 protein in urothelium is required.
Similar articles
-
Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.J Urol. 2001 May;165(5):1481-7. J Urol. 2001. PMID: 11342901
-
Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.Anticancer Res. 2002 Nov-Dec;22(6B):3759-64. Anticancer Res. 2002. PMID: 12552989
-
Molecular and immunohistochemical evaluation of epidermal growth factor receptor and c-erb-B-2 gene product in transitional cell carcinomas of the urinary bladder: a study in Greek patients.Mod Pathol. 1995 Sep;8(7):758-64. Mod Pathol. 1995. PMID: 8539234
-
Molecular genetics and biochemical mechanisms in bladder cancer. Oncogenes, tumor suppressor genes, and growth factors.Urol Clin North Am. 1992 Nov;19(4):629-39. Urol Clin North Am. 1992. PMID: 1441021 Review.
-
[Biochemical prognostic factors of ovarian carcinoma].Zentralbl Gynakol. 1995;117(5):243-6. Zentralbl Gynakol. 1995. PMID: 7793165 Review. German.
Cited by
-
Bladder cancer: can we move beyond chemotherapy?Curr Oncol Rep. 2010 Jul;12(4):278-83. doi: 10.1007/s11912-010-0104-5. Curr Oncol Rep. 2010. PMID: 20446067
-
Over-expression of HER-2 is associated with the stage in carcinomas of the urinary bladder.Libyan J Med. 2012;7. doi: 10.3402/ljm.v7i0.14694. Epub 2012 Mar 8. Libyan J Med. 2012. PMID: 22408683 Free PMC article.
-
Growth factors in bladder cancer.World J Urol. 1995;13(6):349-55. doi: 10.1007/BF00191216. World J Urol. 1995. PMID: 9116754 Review.
-
Confrontation of immunohistochemistry and fluorescent in situ hybridization for the assessment of HER-2/ neu (c-erbb-2) status in urothelial carcinoma.Virchows Arch. 2004 May;444(5):415-9. doi: 10.1007/s00428-004-0986-4. Epub 2004 Mar 17. Virchows Arch. 2004. PMID: 15029496
-
Epidermal growth factor receptor and bladder cancer.Postgrad Med J. 2002 Oct;78(924):584-9. doi: 10.1136/pmj.78.924.584. Postgrad Med J. 2002. PMID: 12415079 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials
Miscellaneous